Phoenox Pharma is an early stage biotech company focusing on delivering mitochondrial inhibitors specifically to cancer stem cells for the treatment of orphan oncology indications of significant unmet need. Cancer stem cells (CSCs) are a phenomenon common to all malignancies and drive recurrent disease, metastasis and ultimately death of the cancer patients. While an attractive target, anti-CSC therapeutic agents are not yet on the market and have been limited by toxicity in clinical trials. Phoenox, through the use of an artificial intelligence platform, is designing novel small molecules that employ a hypoxia-activated prodrug mechanism to deliver payloads targeting multiple facets of mitochondrial respiration and biogenesis. The AI platform will accelerate development by scoring molecules for pharmacokinetic properties based on similarity to known drugs, allowing Phoenox to shorten lead optimization design iterations.